StockpollyBeta
Get App
Popularity #2,272
SLDB · NASDAQ · Biotechnology

Solid Biosciences (SLDB)

Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.

$8.85
vs last close+0.31 (+3.58%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
232227283540404148495757
Research & development171519192731313239384644
678889999111113
General & administrative678889999111113
Other expenses000000000000
Operating income−23−22−27−28−35−40−40−42−48−49−57−57
22332−3122013
Interest income223322233223
Interest expense000000000000
Other non-operating income−2−2−3−3−33−1−2−20−1−3
Income before tax−21−20−24−25−33−43−39−39−46−50−57−55
Net income from continuing operations−21−20−24−25−33−43−39−39−46−50−57−55
Net income−21−20−24−25−33−43−39−39−46−50−57−55
EPS, basic−$1.05−$0.70−$0.64−$0.61−$0.79−$0.80−$0.59−$0.42−$0.48−$0.53−$0.52−$0.38
EPS, diluted−$1.05−$0.70−$0.64−$0.61−$0.79−$0.80−$0.59−$0.42−$0.48−$0.53−$0.52−$0.38
Weighted average shares, basic20293841415466949495110144
Weighted average shares, diluted20293841415466949495110144
EBITDA−20−20−24−24−32−42−39−39−45−49−56−54
Depreciation & amortization100100000001
EBIT−21−20−24−25−33−43−39−39−46−50−57−55